A clinical pharmacology expert specializing in oncology drug development, this physician–scientist has more than 40 years of professional experience in the clinical research and development of anticancer therapies. Their career spans both academic medicine and the pharmaceutical industry and focuses on the clinical development of cytotoxic chemotherapy agents, targeted therapies, and monoclonal antibody treatments. This background includes senior leadership roles in clinical research, oncology medical affairs, and pharmaceutical development programs responsible for advancing investigational cancer therapies through regulatory development pathways.

The expert’s work in oncology clinical pharmacology includes the design and execution of Phase I through Phase IV clinical trials involving both single-agent and combination anticancer therapies. Their experience also includes pharmacokinetic and pharmacodynamic investigations, as well as cardiac safety assessments such as QTc studies conducted in oncology patients. In these roles, the expert has prepared and overseen comprehensive clinical development plans that summarize drug development activities supporting New Drug Application submissions and post-marketing research programs. Their work has involved collaboration with clinical investigators and research centers across the United States, Canada, Europe, Eastern Europe, and Japan, supporting multinational clinical research initiatives in oncology.

Additional aspects of the expert’s work include evaluation of oncology clinical trial methodology, analysis of drug safety and efficacy data, and interpretation of pharmacologic findings generated during cancer drug development programs. Their experience includes leadership roles in oncology medical affairs and participation in the clinical development of multiple investigational anticancer agents, including platinum-based cytotoxic therapies and antiangiogenic monoclonal antibody treatments. The expert has also served as an independent consultant to pharmaceutical companies on projects involving oncology drug development strategy, clinical research planning, and regulatory development.

The expert also has experience providing expert witness services in matters involving oncology drug development and clinical pharmacology issues, including consultation and testimony related to anticancer therapeutics and pharmaceutical development. This work has included participation in litigation matters involving oncology drug development and related patent issues.

Credentials include board certification in Clinical Pharmacology from the American Board of Clinical Pharmacology and medical licensure in the state of Michigan. The expert holds Doctor of Medicine and Doctor of Philosophy degrees and has participated in professional organizations focused on oncology research, cancer pharmacology, and clinical pharmacology and therapeutics.